Remifentanil-based anesthesia is superior to sufentanil in early recovery of patients after laparoscopic nephrolithotomy.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026827

Enrollment

Unknown

Registered

2019-10-23

Start date

2019-10-24

Completion date

Unknown

Last updated

2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic nephrolithotomy

Interventions

2:sufentanil

1:Remifentanil

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The selected subjects were ASA grade I or II patients aged 20-65 years who underwent laparoscopic nephrolithotripsy under general anesthesia.

Exclusion criteria

Exclusion criteria: (1) reoperation; (2) chronic liver and kidney diseases; (3) serious heart and lung diseases; (4) allergies to resufentanil, sufentanil and combination of drugs; (5) poor understanding, mental disorders or central nervous system disorders that can not complete QoR-15; (5) body mass index > 40% or < 22%.

Design outcomes

Primary

Measure	Time frame
Ramsay score;	—

Secondary

Measure	Time frame
HR, BP, SpO2, Respiratory state, consciousness recovery time, orientation recovery time, total dosage of analgesics, VAS score, qor-15 score;	—

Contacts

Public ContactCheng Wei

The People's Hospital of Kizilsu Kirghiz Autonomous Prefecture

53974314@qq.com+86 18796205791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026